In vitro activity of ceftolozane alone and in combination with tazobactam against extended-spectrum-β-lactamase-harboring Enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4521-4525

  Melchers, Maria J B ^a   Van Mil, Anita C H A M ^b   Mouton, Johan W ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CEFTOLOZANE; TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CITROBACTER FREUNDII; CONTROLLED STUDY; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID;

EID: 84939782896     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04498-14     Document Type: Article

References (27)

1. st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14:933-951. http://dx.doi.org/10.1128/CMR.14.4.933-951.2001.
2. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. 1983. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11:315-317. http://dx.doi.org/10.1007/BF01641355.
3. Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657-686. http://dx.doi.org/10.1128/CMR.18.4.657-686.2005.
4. Bush K, Jacoby GA. 2010. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 54:969-976. http://dx.doi.org/10.1128/AAC.01009-09.
5. Drawz SM, Bonomo RA. 2010. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23:160-201. http://dx.doi.org/10.1128/CMR.00037-09.
6. Bassetti M, Ginocchio F, Giacobbe DR, Mikulska M. 2011. Development of antibiotics for Gram-negatives: where now? Clin Invest 1:211-227. http://dx.doi.org/10.4155/cli.10.31.
7. Kanj SS, Kanafani ZA. 2011. Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. May Clin Proc 86:250-259. http://dx.doi.org/10.4065/mcp.2010.0674.
8. th Annu Mee. American Society for Microbiology, Washington, DC.
9. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. 1993. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother 37:851-858. http://dx.doi.org/10.1128/AAC.37.4.851.
10. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. 2012. Beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54:167-174. http://dx.doi.org/10.1093/cid/cir790.
11. Titelman E, Karlsson IM, Ge Y, Giske CG. 2011. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 70:137-141. http://dx.doi.org/10.1016/j.diagmicrobio.2011.02.004.
12. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2011. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 55:2390-2394. http://dx.doi.org/10.1128/AAC.01737-10.
13. Livermore DM, Mushtaq S, Ge Y. 2010. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 65:1972-1974. http://dx.doi.org/10.1093/jac/dkq248.
14. Mouton J, Voss A, Arends J, Bernards S. 2007. Prevalence of ESBL in the Netherlands: the ONE study. Int J Antimicrob Agents 29:S91-S92. http://dx.doi.org/10.1016/S0924-8579(07)70289-3.
15. st informational supplement. CLSI M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
16. International Organization for Standardization. 2006. Clinical laboratory testing and in vitro diagnostic test systems: susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices. Part 1: reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. ISO 20776-1:2006. International Organization for Standardization, Geneva, Switzerland.
17. EUCAST. 2014. Breakpoint tables for interpretation of MICs and zone diameters, version 4.0. http://www.eucast.org/clinical-breakpoints/.
18. Fass RJ, Prior RB. 1989. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother 33:1268-1274. http://dx.doi.org/10.1128/AAC.33.8.1268.
19. nd Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
20. Farrell DJ, Flamm RK, Sader HS, Jones RN. 2013. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob Agents Chemother 57:6305-6310. http://dx.doi.org/10.1128/AAC.01802-13.
21. Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. 2014. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 69:2713-2722. http://dx.doi.org/10.1093/jac/dku184.
22. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, Ayala J, Coque TM, Kern-Zdanowicz I, Luzzaro F, Poirel L, Woodford N. 2007. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 59:165-174. http://dx.doi.org/10.1093/jac/dkl483.
23. Bush K. 2013. Proliferation and significance of clinically relevant beta-lactamases. Ann N Y Acad Sci 1277:84-90. http://dx.doi.org/10.1111/nyas.12023.
24. Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque TM. 2008. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 14(Suppl 1):S144-S153. http://dx.doi.org/10.1111/j.1469-0691.2007.01850.x.
25. Hawkey PM, Jones AM. 2009. The changing epidemiology of resistance. J Antimicrob Chemother 64(Suppl):3-10. http://dx.doi.org/10.1093/jac/dkp256.
26. Livermore DM. 2012. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med 27:128-142. http://dx.doi.org/10.3904/kjim.2012.27.2.128.
27. Canton R, Lumb J. 2011. Emerging resistance in Gram-negative pathogens and implications for clinical practice. Future Microbiol 6:19-22. http://dx.doi.org/10.2217/fmb.10.150.